Cat 1 — 2026MetabolicLongevity

MOTS-c

Mitochondrial ORF of 12S rRNA type-c

Mitochondria-derived peptide discovered in 2015. Acts as an exercise mimetic by activating the same metabolic pathways triggered by physical activity. Levels naturally decline with age.

Evidence

Human data exists

Routes

injectable

Available since

Identified in 2015 by Lee et al. at USC. Research use from approximately 2018 onward. Category 1 compounding access from February 2026.

Mechanism of action

Translocates to the cell nucleus under metabolic stress and activates AMPK — the master cellular energy sensor. Regulates insulin sensitivity, activates the folate cycle, and reduces inflammatory cytokines. Mimics many cellular effects of exercise at the molecular level.

Effects in the body

MOTS-c is produced by your own mitochondria and its levels naturally decline with age. It switches cellular metabolism into an exercise-like state — burning fuel more efficiently, improving insulin sensitivity, and reducing inflammation — without physical activity.

Pros & cons (from the literature)

Pros

Significantly improves insulin sensitivity in animal studies
Exercise-like metabolic signaling demonstrated preclinically
Anti-obesity and anti-diabetic effects in animal models
Anti-inflammatory properties across multiple pathways
May counter age-related metabolic decline

Cautions

Discovered only in 2015 — very limited human clinical data available
No human clinical trials completed as of 2026
Dosing completely experimental — no established protocol
More expensive to manufacture than older peptides
Unknown long-term safety profile in humans

Protocol summary (from published research)

Research protocols: 5–10 mg subcutaneous injection 3–5 times per week. Early-stage protocols vary significantly. Some researchers suggest 5 days on 2 days off cycling. Very early exploratory stage for human use.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Category 1 as of February 2026. Compoundable with physician prescription from licensed 503A pharmacy. One of the newer peptides on the Category 1 list — science is compelling but still early stage for human research.

Evidence base

Discovery paper by Lee et al. published in Cell Metabolism in 2015. Multiple animal studies showing metabolic effects. Human data very limited as of 2026. Mechanism well-established scientifically.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Expert perspective — Dr. Alex Tatem, Urologist

Dr. Alex Tatem is a board-certified Urologist and Men's Health Specialist who has studied peptides for 12 years. Videos featured for educational purposes. ThePeptide.expert is an independent platform.

Dr. Tatem explains MOTS-c — describing it as 'exercise in a vial' for its ability to upregulate energy pathways and improve metabolic function.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.